Welcome to Unit AS 6: Analysis of Medicines and Bioassays

Welcome! When you swallow a painkiller or take an antibiotic, have you ever wondered how scientists ensure that every single tablet contains the exact right amount of medicine? How do they test that a new drug actually works safely in the human body before it hits pharmacy shelves?

In this chapter of Unit AS 6: Medicine, Drugs and Clinical Trials, we explore how medicines are classified, how chemists calculate their exact concentrations using quantitative techniques, how biologists measure drug potency using living systems (bioassays), and how clinical trials protect patients. Don't worry if the calculations or experimental terms seem intimidating at first — we will break everything down step-by-step!

1. Drugs vs. Medicines & How We Classify Them

What is the Difference Between a Drug and a Medicine?

While people often use these two words interchangeably in everyday conversation, they have very specific definitions in pharmaceutical science:

• Drug: Any chemical substance that alters biological function when introduced into the body.
• Medicine: A prepared formulation that contains the Active Pharmaceutical Ingredient (API) combined with inactive substances called excipients (such as binders, colourings, flavourings, and preservatives) designed for therapeutic administration, disease prevention, or diagnosis.

Analogy: Think of a chocolate chip cookie. The chocolate chips are the API (the active part giving the main therapeutic effect), while the flour, butter, and sugar are the excipients (they give the tablet its shape, bulk, stability, and taste).

Classification by Source

Medicines come from three main origins:

1. Natural Products: Derived directly from living organisms or minerals. Examples include plant extracts, microbial by-products (such as penicillin from fungi), and minerals.
2. Semi-Synthetic Compounds: Natural substances that have been chemically modified in a laboratory to improve their effectiveness, reduce side effects, or increase stability.
3. Purely Synthetic Compounds: Designed and manufactured entirely from chemical starting materials in the laboratory.

Classification by Action and Target

Medicines can also be grouped by how they interact with biological targets in the body:

• Receptor Agonists: Molecules that bind to a biological receptor and activate it, triggering a cellular response.
• Receptor Antagonists: Molecules that bind to a receptor and block it, preventing natural chemicals from binding and producing a response.
• Enzyme Inhibitors: Substances that bind to specific enzymes and decrease or halt their catalytic activity.
• Antimicrobial Agents: Compounds that kill or inhibit the growth of microorganisms such as bacteria.
• Ion-Channel Blockers: Drugs that prevent the flow of specific ions across cell membranes by blocking ion channels.

Section Takeaway: A medicine is an API plus excipients. Medicines are categorised by where they come from (natural, semi-synthetic, synthetic) and how they act on specific biological targets.

2. Quantitative Analysis of Medicines

Pharmaceutical quality control ensures that tablets and liquid suspensions contain the stated amount of API and are safe for patient use. Chemists rely on precise analytical techniques to calculate purity and percentage composition.

Volumetric and Titrimetric Analysis

Titration is a fundamental laboratory method used to determine the concentration of an active ingredient.

• Standard Acid-Base Titrations: Direct neutralization reactions used to determine basic or acidic drug components.
• Back Titrations: Used when an API is insoluble in water or reacts too slowly for a standard direct titration. In a back titration, an excess of a standard reagent is added to react completely with the active substance. The remaining (unreacted) excess reagent is then titrated against a second standard solution to calculate how much reagent reacted with the drug.

Real-World Applications: Assessing the quantity of acetylsalicylic acid in aspirin tablets, or measuring the neutralisation capacity of antacid tablets.

Spectrophotometry, Colorimetry and the Beer-Lambert Law

Many drug solutions absorb specific wavelengths of light. We can measure how much light passes through a solution using a colorimeter or spectrophotometer to determine the drug's concentration.

The relationship between absorbance and concentration is defined by the Beer-Lambert Law:

\(A = \varepsilon c l\)

Where:
• \(A\) = Absorbance (unitless measure of light absorbed)
• \(\varepsilon\) = Molar absorptivity (a constant specific to the substance and wavelength)
• \(c\) = Concentration of the active drug substance
• \(l\) = Path length of the light beam through the sample cell (cuvette, usually \(1\text{ cm}\))

Constructing and Using a Calibration Curve

To find the unknown concentration of an API in a liquid medicine, scientists use the following step-by-step procedure:

1. Prepare Serial Dilutions: Make a series of standard solutions with known, accurate concentrations of the pure drug substance.
2. Measure Absorbance: Record the absorbance of each standard solution at a specific wavelength.
3. Plot the Calibration Curve: Plot absorbance on the \(y\)-axis against concentration on the \(x\)-axis to obtain a straight, linear line of best fit passing through the origin.
4. Measure the Unknown Sample: Record the absorbance of the medicine sample.
5. Interpolate: Find the measured absorbance on the \(y\)-axis, read across to the line of best fit, and read down to find the unknown concentration on the \(x\)-axis.

Important Laboratory Rule: Interpolation vs Extrapolation:
Always interpolate (read within the range of known standard points). Never extrapolate (extend the line beyond the highest concentration standard), because at higher concentrations the Beer-Lambert Law is no longer linear.

Handling Dilution Factors in Calculations

In quality control assays, tablets are often crushed, dissolved in a large flask (e.g. \(250\text{ cm}^3\)), and only a small portion (e.g. a \(25\text{ cm}^3\) aliquot) is titrated or analysed.

Crucial Calculation Step: Remember to scale up! If \(25\text{ cm}^3\) was used out of a \(250\text{ cm}^3\) volumetric flask, you must multiply the calculated moles of API by a dilution factor of 10 (\(250 / 25 = 10\)) to determine the total mass of API in the original tablet.

Section Takeaway: Quantitative analysis uses back titrations and spectrophotometry (Beer-Lambert Law) with calibration curves to determine the exact concentration and percentage composition of APIs.

3. Bioassays and Biological Potency Testing

What is a Bioassay?

A bioassay is an analytical method used to determine the potency, concentration, or biological activity of a substance by measuring its effect on living cells, isolated tissues, or microorganisms compared against an agreed reference standard.

Why do we need bioassays instead of just chemical assays?
A standard chemical assay (like titration) tells you the chemical quantity of a molecule present, but it cannot tell you if the drug is biologically active or how a complex biological system will respond. Bioassays are essential for biologics, complex mixtures, vaccines, and antibiotics where chemical structure alone cannot reliably predict biological potency.

Types of Bioassays

1. Quantal (All-or-None) Assays:
These measure whether a specific biological response happens or does not happen across a population of test subjects.
• \(LD_{50}\) (Lethal Dose 50%): The dose of a substance required to kill 50% of a tested population.
• \(ED_{50}\) (Effective Dose 50%): The dose required to produce a specific therapeutic effect in 50% of a tested population.

2. Graded Assays:
These measure the magnitude of a biological response that changes proportionally with the drug concentration.
• Examples include measuring the contraction force of isolated smooth muscle tissue or the clearance zone diameter around an antibiotic disc.

Microbiological Bioassays (Antibiotic Potency)

An agar diffusion assay is a classic graded bioassay used to test antibiotic potency:

1. An agar plate is uniformly inoculated with a target bacterial strain.
2. Wells or filter paper discs containing known standard concentrations of the antibiotic and the unknown test sample are placed onto the agar.
3. As the antibiotic diffuses outward, it stops bacterial growth, creating a clear circular zone of inhibition.
4. The diameter of the zone of inhibition is directly proportional to the logarithm of antibiotic concentration.
5. By plotting a standard curve of zone diameter versus concentration for known standards, the potency of the unknown antibiotic sample is determined.

Dose-Response Relationships

When biological response is plotted against the logarithm of drug dose, a characteristic sigmoidal (S-shaped) logarithmic dose-response curve is produced.

• Maximal Efficacy (\(E_{\max}\)): The maximum biological response that the drug can produce, regardless of how high the dose is increased.
• Potency (\(EC_{50}\) / \(ED_{50}\)): The concentration or dose of a drug required to produce 50% of its maximal response. A drug that achieves its half-maximal effect at a lower concentration is considered more potent.

Section Takeaway: Bioassays assess biological potency using living systems. Quantal assays evaluate all-or-none responses (\(LD_{50}\), \(ED_{50}\)), while graded assays evaluate proportional responses (such as zones of inhibition in antibiotic assays).

4. From Lab to Patient: Pre-Clinical Testing & Clinical Trials

Before any medicine can be prescribed by doctors, it must go through an extensive, highly regulated development pipeline.

Pre-Clinical Development

Before a new substance is ever given to a human, it undergoes pre-clinical laboratory testing:

• In Vitro Testing: Experiments conducted outside a living organism, such as in test tubes or cell cultures.
• In Vivo Testing: Experiments conducted in living animals.
• Aims of Pre-Clinical Testing: To establish pharmacodynamics (what the drug does to the body), pharmacokinetics (what the body does to the drug, known as ADME: Absorption, Distribution, Metabolism, and Excretion), safe starting doses, and toxicological profiles.

The Phases of Human Clinical Trials

If pre-clinical results are promising, the drug moves into human clinical trials, which occur in four distinct phases:

Phase I: Safety and Tolerability
• Participants: A small group of 20 to 80 healthy volunteers.
• Main Purpose: Assesses drug safety, tolerability, side effects, and safe dosage ranges in humans.

Phase II: Therapeutic Efficacy
• Participants: A medium group of 100 to 300 patient volunteers suffering from the target disease.
• Main Purpose: Evaluates whether the drug actually works (therapeutic efficacy) and helps determine optimal dosing regimens.

Phase III: Large-Scale Comparison
• Participants: A large, multi-centre cohort of 1,000 to 3,000+ patients.
• Main Purpose: Confirms efficacy, monitors adverse reactions in a broader demographic, and compares the new drug directly against current gold-standard treatments or placebos.

Phase IV: Post-Marketing Surveillance
• Participants: The general public after the drug has received regulatory approval and is on the market.
• Main Purpose: Long-term safety monitoring to track rare adverse events and long-term effects (e.g. via the Yellow Card Scheme in the UK).

Clinical Trial Design, Controls, and Ethics

To eliminate bias and ensure patient safety, trials follow strict designs:

• Placebo: An inert substance (like a sugar pill) that has no therapeutic effect, used as a baseline control.
• Single-Blind Study: The patient does not know whether they are receiving the active drug or the placebo, preventing psychological bias.
• Double-Blind Study: Neither the patient nor the administering doctor/researcher knows who is receiving the active drug or the placebo, eliminating experimental and observer bias.
• Randomised Controlled Trial (RCT): Participants are randomly assigned to either the experimental group or the control group.
• Regulatory & Ethical Oversight: Independent Research Ethics Committees safeguard participant rights and well-being, while regulatory bodies such as the MHRA (Medicines and Healthcare products Regulatory Agency) review data and approve medicines.

Section Takeaway: Drug development progresses from pre-clinical studies (in vitro/in vivo, ADME) through Phase I (healthy volunteers), Phase II (target patients), Phase III (large comparative multi-centre trial), and Phase IV (post-marketing safety monitoring).

5. Quick Summary & Pitfall Checklist

Common Mistakes to Avoid in Exams:

• Confusing Phase I and Phase II: Remember that Phase I uses a small group of healthy volunteers to test safety and pharmacokinetics. Phase II is the first phase that uses patients with the disease to test efficacy.
• Bioassay vs Chemical Assay: Chemical assays measure physical/chemical quantities (e.g. mass, concentration). Bioassays measure the biological potency/effect of a substance on living systems.
• Extrapolation Error: Never extrapolate beyond your highest standard on a calibration curve — always interpolate within the linear range.
• Dilution Factors: When calculating the mass of an API in a whole tablet from a titration, always remember to multiply by the dilution factor if only a portion of the dissolved solution was titrated.

Mnemonic for Clinical Trials:
• Phase I: Individuals who are healthy (Safety)
• Phase II: Ill patients (Efficacy)
• Phase III: Immense population (Comparison)
• Phase IV: Inspecting the market (Yellow Card Scheme)